Goldman Sachs’s Accelerate Diagnostics AXDX Stock Holding History

Goldman Sachs’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-2,500	Closed	-$359K	–	7015
2016 Q1	$359K	Buy	+2,500	New	+$353K	﹤0.01%	5082

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Goldman Sachs's AXDX Position: Q1 2023 in Review

Goldman Sachs sold out of Accelerate Diagnostics (AXDX) in Q1 2023, closing a stake of 3,887 shares — an estimated $27.4K sold.

Goldman Sachs first reported a position in AXDX in Q2 2013 and held it in 36 quarters. The position peaked at $4.6M in Q1 2014. 67 funds tracked by Wall St. Rank hold AXDX as of Q1 2023.

Goldman Sachs reported no remaining Accelerate Diagnostics position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 3,887 Accelerate Diagnostics shares in Q1 2023, an estimated $27.4K.
Goldman Sachs first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 36 quarters.
Goldman Sachs's Accelerate Diagnostics position peaked at $4.6M in Q1 2014.
67 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.